Predicting peritoneal metastasis in gastric cancer using radiomics
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics: a Multi-center Prospective Study
This study is testing a new system that uses CT scans to help doctors predict the risk of cancer spreading in patients with advanced gastric cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese Academy of Sciences Government |
| Locations | 13 sites (Beijing and 12 other locations) |
| Trial ID | NCT05722275 on ClinicalTrials.gov |
What this trial studies
This study aims to develop an intelligent analysis system that utilizes radiomics to predict the risk of peritoneal metastasis in patients with advanced gastric cancer. By analyzing conventional CT images, the system will extract and combine relevant radiomic features to improve detection and facilitate timely treatment decisions. The study will validate the effectiveness of this approach through observational methods, focusing on patients diagnosed with advanced gastric cancer who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with advanced gastric cancer (≥cT3) who do not show typical signs of peritoneal metastasis on CT.
Not a fit: Patients with previous abdominal surgeries or those with other malignancies or inflammatory diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection of peritoneal metastasis, allowing for more timely and personalized treatment options for gastric cancer patients.
How similar studies have performed: While the use of radiomics in cancer detection is a growing field, this specific approach to predicting peritoneal metastasis in gastric cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) diagnosed advanced gastric cancer (≥cT3) by endoscopy-biopsy pathology, combined with CT and/or endoscopic ultrasound; * (2) with both enhanced CT and laparoscopy; * (3) without typical peritoneal metastasis indications in CT (diffuse omental nodules or omental cake, large amount of ascites, obvious irregular thickening with high peritoneal enhancement); * (4) without other evidence of distant metastasis, and no stage IV features on CT. Exclusion Criteria: * (1) previous abdominal surgery; * (2) previous abdominal malignancies or inflammatory diseases; * (3) time intervals between CT and laparoscopy longer than 2 weeks; * (4) CT image artifacts that undermine peritoneal lesion assessment.
Where this trial is running
Beijing and 12 other locations
- Peking University Cancer Hospital & Institute — Beijing, China (Recruiting)
- Fujian Medical University Union Hospital — Fuzhou, China (Recruiting)
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University — Guangzhou, China (Recruiting)
- Guangdong Provincial People's Hospital — Guangzhou, China (Recruiting)
- Nanfang Hospital of Southern Medical University — Guangzhou, China (Recruiting)
- Sun Yat-Sen University Cancer Hospital — Guangzhou, China (Recruiting)
- Guizhou Provincial People's Hospital — Guiyang, China (Recruiting)
- Yunnan Cancer Hospital — Kunming, China (Recruiting)
- Shanxi Province Cancer Hospital — Taiyuan, China (Recruiting)
- Henan Cancer Hospital — Zhengzhou, China (Recruiting)
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, China (Recruiting)
- Zhenjiang First People's Hospital — Zhenjiang, China (Recruiting)
- Scientific Institute San Raffaele — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Di Dong, Ph.D
- Email: di.dong@ia.ac.cn
- Phone: +86 010-82618465
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.